• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Bright Green Corporation

    12/22/22 5:00:06 PM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BGXX alert in real time by email
    SC 13D 1 form13d.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )

     

    BRIGHT GREEN CORPORATION

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    10920G100

    (CUSIP Number)

     

    Terry Rafih

    1033 George Hanosh Boulevard

    Grants, NM 87020

    (833) 658-1799

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

     

    December 12, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    CUSIP No. 10920G100

     

    1

    NAME OF REPORTING PERSON

     

    Terry Rafih

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a) ☐

    (b) ☐ 

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS (See Instructions)

     

    PF

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

         

     

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Canada

     

    Number of Shares Beneficially Owned by Each Reporting Person With

     

    7

    SOLE VOTING POWER

     

    23,005,000(1)

    8

    SHARED VOTING POWER

     

    0

    9

    SOLE DISPOSITIVE POWER

     

    23,005,000(1)

    10

    SHARED DISPOSITIVE POWER

     

    0

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    23,005,000(1)

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

         

     

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    13.35% (2)

    14

    TYPE OF REPORTING PERSON

     

    IN

     

    (1) Includes 3,000,000 shares of common stock, par value $0.0001 per share (the “Common Stock”), which became fully vested and non-forfeitable upon the issuance of such shares on December 12, 2022, in accordance with the Executive Employment Agreement entered into between Terry Rafih (the “Reporting Person”) and Bright Green Corporation (the “Issuer”) on September 22, 2022, effective as of September 1, 2022. Does not include 7,000,000 shares of Common Stock, which shall vest and become non-forfeitable on a quarterly basis over a period of two years commencing on December 12, 2022, provided the Reporting Person remains in continuous service on behalf of the Issuer.
    (2) Based on 169,342,300 shares of Common Stock issued and outstanding as of October 28, 2022, as reported in the Issuer’s definitive proxy statement, filed by the Issuer with the Securities and Exchange Commission (the “SEC”) on November 10, 2022.

     

    2
     

     

    This Schedule 13D is being filed by the Reporting Person with respect to Common Stock of the Issuer.

     

    ITEM 1. Security and Issuer.

     

    The class of equity security to which this Schedule 13D relates is the Common Stock of the Issuer. The address of the principal executive offices of the Issuer is 1033 George Hanosh Boulevard, Grants, NM 87020. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

     

    ITEM 2. Identity and Background.

     

    (a) This Schedule 13D is being filed by Terry Rafih.

     

    (b) The business address of the Reporting Person is c/o Bright Green Corporation, 1033 George Hanosh Boulevard, Grants, NM 87020.

     

    (c) Mr. Rafih is the owner and Chief Executive Officer of Rafih Automotive Group. The principal office of Rafih Automotive Group is 9375 Tecumseh Rd, Windsor, ON N8R 1A1.

     

    (d), (e) During the last five years, the Reporting Person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and, was not or is not subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. During the last five years, the Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    (f) Canada.

     

    ITEM 3. Source and Amount of Funds or Other Consideration.

     

    On December 12, 2022, the stockholders of the Issuer approved the issuance of up to 10,00,000 shares of Common Stock to the Reporting Person, in accordance with the Executive Employment Agreement entered into between the Reporting Person and the Issuer on September 22, 2022 (effective as of September 1, 2022). 3,000,000 of such shares of Common Stock became fully vested and non-forfeitable upon stockholder approval on December 12, 2022. The remaining 7,000,000 shares of Common Stock shall vest and become non-forfeitable on a quarterly basis over a period of two years commencing on December 12, 2022, provided the Reporting Person remains in continuous service on behalf of the Issuer.

     

    ITEM 4. Purpose of Transaction.

     

    The Reporting Person is the Chief Executive Officer and the Chairman of the Board of Directors of the Issuer. In this capacity, the Reporting Person takes and will continue to take an active role in the Issuer’s strategic direction. Additionally, in his capacity as stockholder of the Issuer, the Reporting Person reviews and intends to continue to review, on an ongoing and continued basis, his investments in the Issuer. Depending on the factors discussed below and subject to applicable law, the Reporting Person may from time to time acquire additional securities of the Issuer or otherwise dispose of some or all of such securities of the Issuer. Any transactions that the Reporting Person may pursue may be made at any time and from time to time without prior notice and will depend upon a variety of factors, including, without limitation, current and anticipated future trading prices of the securities of the Issuer, the financial condition, results of operations and prospects of the Issuer, general economic, financial market and industry conditions, other investment and business opportunities available to the Reporting Person, tax considerations and other factors.

     

    Other than as described above and other than in his capacity as Chief Executive Officer and Chairman of the Board of Directors of the Issuer, the Reporting Person does not currently have any plans or proposals that relate to or would result in any of the transactions involving the Issuer described in subparagraphs (a) through (j) of Item 4 of Schedule 13D (although the Reporting Person may from time to time consider pursuing or proposing any such transactions and, in such event, may discuss, evaluate and/or pursue any such transactions with their respective advisors, the Issuer or other persons).

     

    3
     

     

    ITEM 5. Interest in Securities of the Issuer.

     

    (a), (b) The responses of the Reporting Person with respect to Rows 7 through 13 of the respective cover pages of the individual Reporting Person to this Schedule 13D are incorporated herein by reference.

     

    The Reporting Person’ aggregate percentage of beneficial ownership is approximately 13.35% of the outstanding Common Stock. Calculations of the percentage is based on 169,342,300 shares of Common Stock issued and outstanding as of as of October 28, 2022, as reported in the Issuer’s definitive proxy statement, filed by the Issuer with the SEC on November 10, 2022.

     

    (c) To the best knowledge of the Reporting Person, except as set forth in this Schedule 13D, the Reporting Person has not engaged in any transaction with respect to the Common Stock during the sixty days prior to the date of filing of this Schedule 13D.

     

    (d) Not applicable.

     

    (e) Not applicable.

     

    ITEM 6. Contracts, Arrangements, Understandings or Relationship with Respect to the Securities of the Issuer.

     

    Except as set forth herein, there are no contracts, arrangements, understandings or relationships by the Reporting Person and any other person with respect to the Common Stock.

     

    ITEM 7. Material to Be Filed as Exhibits.

     

    Not applicable.

     

    4
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: December 22, 2022

     

    By: /s/ Terry Rafih  
    Name: Terry Rafih  
    Title: Chief Executive Officer & Chairman of the Board  

     

    5

    Get the next $BGXX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BGXX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BGXX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bright Green Corporation Announces the next steps for the completion of its restructuring plan

      FORT LAUDERDALE, FLORIDA, March 21, 2025 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC:BGXX) ("Bright Green" or the "Company") announced that on March 17, 2025, on behalf of the Company, Lynn Stockwell has asked the court to approve the "RSA" Restructuring Security Agreement, Disclosure Statement and Plan. The highlights of the Plan and Disclosure will provide new equity for the company to pay all creditors with approved claims in full, in addition the Company equity shareholders will retain their interests in the Company and are unimpaired with no dilution. Lynn Stockwell, the new Chief Executive Officer and Chairman of the Board of Directors of Bright Green Corporation, is also the

      3/21/25 9:15:00 AM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bright Green Corporation Announces the completion of its restructuring plan, withdraws from the Cannabis business and sets course on the production of all DEA Scheduled Controlled Substances

      FORT LAUDERDALE, FLORIDA, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC:BGXX) ("Bright Green" or the "Company") announced that on February 24, 2025, on behalf of the Company, Lynn Stockwell has asked the court to approve the "RSA" Restructuring Security Agreement. The highlights of the RSA will provide new equity for the company to pay all creditors with approved claims in full, in addition the Company equity shareholders will retain their interests in the Company and are unimpaired with no dilution. The Company in its restructuring efforts has entered into an agreement with the DEA to immediately withdraw all Cannabis related renewal applications. This agreement will a

      2/24/25 9:15:00 AM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bright Green Corporation Has Signed Agreement with Majority Shareholder as Plan Sponsor on Prepackaged Plan to Restructure the Company.

      The Company plans to emerge with federal loan guarantees for its 60 new mega farm owner/operators, that collectively will invest $3.5 billion to supply and strengthen the Drugs Made in America supply Chain. FORT LAUDERDALE, FLORIDA, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC:BGXX) ("Bright Green" or the "Company") announced that on January 21, 2025, it has entered into a Restructuring Support Agreement (the "RSA") with Lynn Stockwell, a major shareholder of the Company (the "Plan Sponsor") to restructure the Company. To implement the terms of the RSA, the Company will file, and the Plan Sponsor will support the Company's Prepackaged Plan of Reorganization Under Chapte

      1/27/25 8:17:00 PM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care

    $BGXX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $BGXX
    SEC Filings

    See more

    $BGXX
    Leadership Updates

    Live Leadership Updates

    See more

    $BGXX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Chief Financial Officer Elmasri Saleem sold $4,951 worth of shares (25,942 units at $0.19), decreasing direct ownership by 2% to 1,103,476 units (SEC Form 4)

      4 - Bright Green Corp (0001886799) (Issuer)

      9/11/24 4:05:11 PM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Elmasri Saleem sold $14,313 worth of shares (71,809 units at $0.20), decreasing direct ownership by 6% to 1,129,418 units (SEC Form 4)

      4 - Bright Green Corp (0001886799) (Issuer)

      9/10/24 4:05:08 PM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: Chief Executive Officer Singh Gurvinder was granted 5,500,000 shares (SEC Form 4)

      4/A - Bright Green Corp (0001886799) (Issuer)

      9/9/24 4:05:32 PM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 25-NSE filed by Bright Green Corporation

      25-NSE - Bright Green Corp (0001886799) (Subject)

      3/21/25 11:19:49 AM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bright Green Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Bright Green Corp (0001886799) (Filer)

      3/21/25 9:15:14 AM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bright Green Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Financial Statements and Exhibits

      8-K - Bright Green Corp (0001886799) (Filer)

      2/27/25 4:05:24 PM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • (Updated) U.S. Legal Cannabis Pioneer Bright Green Corporation Appoints Industry Veteran Groovy Singh as New Chief Executive Officer

      Singh's appointment comes in support of the Company's next evolution, which will be focused on investing in top talent, commencement of commercial operations, and investing in clinical research and development of plant based therapies, and expanding into cultivation and manufacturing of other scheduled substances. GRANTS, N.M., Jan. 14, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or "the Company"), announced today their appointment of Groovy Singh, a renowned leader and strategist in the cannabis and wellness industries, as Chief Executive Officer. Singh will replace current CEO Seamus McAuley, who is stepping back from the position to address recently

      1/14/24 10:00:00 AM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • U.S. Legal Cannabis Pioneer Bright Green Corporation Appoints Industry Veteran Groovy Singh as New Chief Executive Officer

      Singh's appointment comes in support of the Company's next evolution, which will be focused on investing in top talent, commencement of commercial operations, and investing in clinical research and development of plant based therapies, and expanding into cultivation and manufacturing of other scheduled substances. GRANTS, N.M., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or "the Company"), announced today their appointment of Groovy Singh, a renowned leader and strategist in the cannabis and wellness industries, as Chief Executive Officer. Singh will replace current CEO Seamus McAuley, who is stepping back from the position to address recently

      10/3/23 11:11:00 AM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bright Green Announces First Quarter 2023 Financial Update and Milestone Progress

      Bright Green has achieved several key milestones throughout the Quarter significantly advancing progress against its strategic plan, including a historic DEA Federal Registration and License Approval. Commencement of its fundamental capital raise of $500+ million utilizing the U.S. Citizen & Immigration Services EB-5 program, alongside the recently announced full acquisition of Alterola Biotech, showcases the Company's significant progress against its strategic plan. Company has raised short-term working Capital of $5.26m to commence its operations as it looks to capitalize on its historic DEA Registration in Q2 2023 and beyond. GRANTS, N.M., May 24, 2023 (GLOBE NEWSWIRE) -- Brig

      5/24/23 8:00:00 AM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D/A filed by Bright Green Corporation (Amendment)

      SC 13D/A - Bright Green Corp (0001886799) (Subject)

      9/6/23 5:19:19 PM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D filed by Bright Green Corporation

      SC 13D - Bright Green Corp (0001886799) (Subject)

      6/15/23 4:30:21 PM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Bright Green Corporation (Amendment)

      SC 13G/A - Bright Green Corp (0001886799) (Subject)

      6/12/23 5:28:12 PM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care